SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Yining Yang, Xiaorui Wang, Chun Wang, Youwen Qin, A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia, International Journal of Hematology, 2015, 101, 2, 165

    CrossRef

  2. 2
    Maria L. Randi, Giulia Geranio, Irene Bertozzi, Concetta Micalizzi, Ugo Ramenghi, Fabio Tucci, Lucia D. Notarangelo, Saverio Ladogana, Giuseppe Menna, Paola Giordano, Caterina Consarino, Piero Farruggia, Giulio A. Zanazzo, Giovanni M. Fiori, Roberta Burnelli, Giovanna Russo, Momcilo Jankovich, Edoardo Peroni, Elena Duner, Giuseppe Basso, Fabrizio Fabris, Maria C. Putti, Are all cases of paediatric essential thrombocythaemia really myeloproliferative neoplasms? Analysis of a large cohort, British Journal of Haematology, 2015, 169, 4
  3. 3
    Adrian P. Trifa, Radu A. Popp, Andrei Cucuianu, Claudia Bănescu, Mihaela Tevet, Bianca Martin, Meilin Murat, Ştefan C. Vesa, Delia Dima, Marcela Cândea, Mariela S. Militaru, Ioan V. Pop, CALR versus JAK2 mutated essential thrombocythaemia – a report on 141 patients, British Journal of Haematology, 2015, 168, 1
  4. 4
    X Cabagnols, J P Defour, V Ugo, J C Ianotto, P Mossuz, J Mondet, F Girodon, J H Alexandre, O Mansier, J F Viallard, E Lippert, A Murati, M J Mozziconacci, P Saussoy, M C Vekemans, L Knoops, F Pasquier, V Ribrag, E Solary, I Plo, S N Constantinescu, N Casadevall, W Vainchenker, C Marzac, O Bluteau, Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution, Leukemia, 2015, 29, 1, 249

    CrossRef

  5. 5
    Amy V. Jones, Daniel Ward, Matthew Lyon, William Leung, Alison Callaway, Andrew Chase, Carolyn L. Dent, Helen E. White, Hans G. Drexler, Jyoti Nangalia, Chris Mattocks, Nicholas C.P. Cross, Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms, Leukemia Research, 2015, 39, 1, 82

    CrossRef

  6. 6
    Éva Pósfai, Imelda Marton, Péter Attila Király, Balázs Kotosz, Zsuzsanna Kiss-László, Márta Széll, Zita Borbényi, JAK2 V617F, MPL, and CALR Mutations in Essential Thrombocythaemia and Major Thrombotic Complications: A Single-Institute Retrospective Analysis, Pathology & Oncology Research, 2015,

    CrossRef

  7. 7
    Stephen E. Langabeer, Hajnalka Andrikovics, Julia Asp, Beatriz Bellosillo, Serge Carillo, Karl Haslam, Lasse Kjaer, Eric Lippert, Olivier Mansier, Elisabeth Oppliger Leibundgut, Melanie J. Percy, Naomi Porret, Lars Palmqvist, Jiri Schwarz, Mary F. McMullin, Susanne Schnittger, Niels Pallisgaard, Sylvie Hermouet, Molecular diagnostics of myeloproliferative neoplasms, European Journal of Haematology, 2015, 94, 6
  8. 8
    F Palandri, R Latagliata, N Polverelli, A Tieghi, M Crugnola, B Martino, M Perricone, M Breccia, E Ottaviani, N Testoni, F Merli, F Aversa, G Alimena, M Cavo, G Martinelli, L Catani, M Baccarani, N Vianelli, Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis, Leukemia, 2015,

    CrossRef

  9. You have free access to this content9
    Ayalew Tefferi, Tiziano Barbui, Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management, American Journal of Hematology, 2015, 90, 2
  10. 10
    Nancy Labastida-Mercado, Samantha Galindo-Becerra, Javier Garcés-Eisele, Perla Colunga-Pedraza, Valeria Guzman-Olvera, Virginia Reyes-Nuñez, Guillermo J. Ruiz-Delgado, Guillermo J. Ruiz-Argüelles, The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms, Hematology/Oncology and Stem Cell Therapy, 2015, 8, 1, 16

    CrossRef

  11. 11
    Stefan Schmidt, ASH 2013: short review on myeloproliferative neoplasms, memo - Magazine of European Medical Oncology, 2014, 7, 3, 138

    CrossRef

  12. 12
    Chih-Cheng Chen, Jyh-Pyng Gau, Hui-Ju Chou, Jie-Yu You, Cih-En Huang, Yi-Yang Chen, Jrhau Lung, Yi-Sheng Chou, Yu-Wei Leu, Chang-Hsien Lu, Kuan-Der Lee, Ying-Huang Tsai, Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia, Annals of Hematology, 2014, 93, 12, 2029

    CrossRef

  13. 13
    A. Tefferi, P. Guglielmelli, D. R. Larson, C. Finke, E. A. Wassie, L. Pieri, N. Gangat, R. Fjerza, A. A. Belachew, T. L. Lasho, R. P. Ketterling, C. A. Hanson, A. Rambaldi, G. Finazzi, J. Thiele, T. Barbui, A. Pardanani, A. M. Vannucchi, Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis, Blood, 2014, 124, 16, 2507

    CrossRef

  14. 14
    J. Nangalia, T. R. Green, The evolving genomic landscape of myeloproliferative neoplasms, Hematology, 2014, 2014, 1, 287

    CrossRef

  15. 15
    John O. Mascarenhas, Nicholas C.P. Cross, Ruben A. Mesa, The future of JAK inhibition in myelofibrosis and beyond, Blood Reviews, 2014, 28, 5, 189

    CrossRef

  16. 16
    A. Tefferi, T. L. Lasho, A. Tischer, E. A. Wassie, C. M. Finke, A. A. Belachew, R. P. Ketterling, C. A. Hanson, A. D. Pardanani, The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants, Blood, 2014, 124, 15, 2465

    CrossRef